SRPT Stock Recent News

Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations & Corporate Communications Douglas Ingram - President & Chief Executive Officer Dallan Murray - Executive Vice President & Chief Customer Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer & Head of Research & Development Ian Estepan - Executive Vice President and Chief Financial Officer Conference Call Participants Operator Good afternoon and welcome to the Sarepta Therapeutics First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.

Sarepta (SRPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2024 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sare.

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

Regenxbio reported some favorable data from a phase 1 clinical trial. Sarepta Therapeutics has a medicine on the market for the same target.

Sarepta Therapeutics is trying to widen its market for Elevidys. Regulators should deliver a verdict in early March.

Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.

Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript

The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.